BioIntelliSense
PrivateLast Round
Series B
Dec 4, 2025
Total Funding Raised
$84.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
BioIntelliSense operates in Healthcare & Life Sciences and is based in Golden, Colorado. Its latest recorded funding round was a Series B round in July 2021.
BioIntelliSense is a health technology company that provides a medical-grade Data-as-a-Service (DaaS) platform for continuous remote patient monitoring and clinical intelligence.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Telemedicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Hardware + Subscription, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioIntelliSense Comparables
Compare BioIntelliSense with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biobeat | 88% | |
| VitalConnect | 88% | |
| Vivalink | 84% |
For institutional investors. Book with your work email.
BioIntelliSense Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 4, 2025 | ||||
| Series C | Dec 1, 2025 | ||||
| Series B | Jul 28, 2021 | ||||
| Grant | Dec 22, 2020 | ||||
| Series A Extension | Sep 8, 2020 | ||||
Series A | Jul 9, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioIntelliSense Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 7wire Ventures | Series B |
| Chimera Investment LLC | Series B |
| TripleTree | Series A, Series B |
| U.S. Department of War | Grant |
| Fresenius Medical Care North America | Series A, Series B |
| Pendrell Corporation | Series B |
| Chimera Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 24, 2026
Solution implemented for Alaska's Rural Health Transformation Program.
- Jan 1, 2026
BioButton® multiparameter wearable device received FDA clearance.
For institutional investors. Book with your work email.
BioIntelliSense Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioIntelliSense's valuation, stock price, and market status.
Is BioIntelliSense a public or private company?
BioIntelliSense is a private company.
What is the current stock price of BioIntelliSense?
BioIntelliSense is a private company, so its shares have no public market price. Caplight tracks BioIntelliSense's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioIntelliSense worth (valuation)?
Valuation information for BioIntelliSense is not publicly available.
Can I buy BioIntelliSense stock?
BioIntelliSense shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioIntelliSense's last funding round?
BioIntelliSense's most recent funding round was Series B on December 4, 2025.
Who are the main investors in BioIntelliSense?
Key investors in BioIntelliSense include Chimera Investment LLC, Chimera Capital, Chimera.
Will BioIntelliSense IPO soon?
No public IPO plans have been announced for BioIntelliSense.
How can I track BioIntelliSense secondary market activity?
Caplight tracks bids, offers, and trades in BioIntelliSense's shares on secondary markets.